The Perigenomed project in France is exploring the feasibility of routine genome sequencing as part of newborn screening. With 500 babies sequenced to date and expansion plans to sequence 2,500 newborns across multiple hospitals, the project targets early detection of hundreds of treatable rare diseases. Sequencing utilizes Illumina NovaSeq X Plus technology, offering personalized and early medical interventions. A second phase will examine clinical utility, technology performance, and economic factors to argue for adoption of genomic newborn screening nationally by 2030.